TY - JOUR
T1 - Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT
AU - Valenta, Ines
AU - Quercioli, Alessandra
AU - Vincenti, Gabriella
AU - Nkoulou, René
AU - Dewarrat, Stephan
AU - Rager, Olivier
AU - Zaidi, Habib
AU - Seimbille, Yann
AU - MacH, Francois
AU - Ratib, Osman
AU - Schindler, Thomas H.
N1 - Funding Information:
The authors thank Christina Laemmli and Claude Ponsolle for assisting in the PET studies, and the cyclotron staff for 13N-ammonia production. No potential conflict of interest exists. This study was supported by the Swiss National Science Foundation (SNF Grant: 3200B0-122237), the Department of Internal Medicine of the University Hospitals of Geneva (Switzerland) and Fellowship grants from the Novartis Foundation (A. Quercioli, MD), and the European Society of Cardiology (ESC) and the Italian Society of Cardiology (Societa‘ Italiana di Cardiologia; SIC) (G. Vincenti, MD).
PY - 2010/12
Y1 - 2010/12
N2 - Background. The aim of this study was to determine whether epicardial structural disease may affect the manifestation of a longitudinal decrease in myocardial blood flow (MBF) or MBF difference during hyperemia in cardiovascular risk individuals, and its dependency on the flow increase. Methods and Results. In 54 cardiovascular risk individuals (at risk) and in 26 healthy controls, MBF was measured with 13N-ammonia and PET/CT in mL/g/min at rest and during dipyridamole stimulation. Computed tomography coronary angiography (CTA) was performed using a 64-slice CT of a PET/CT system. Absolute MBFs during dipyridamole stimulation were mildly lower in the mid-distal than in the mid-LV myocardium in controls (2.20 ± .51 vs 2.29 ± .51, P < .0001), while it was more pronounced in at risk with normal and abnormal CTA (1.56 ± .42 vs 1.91 ± .46 and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respectively, P < .0001), resulting in a longitudinal MBF difference that was highest in at risk with normal CTA, intermediate in at risk abnormal CTA, and lowest in controls (.35 ± .16 and .22 ± .09 vs .09 ± .04 mL/g/min, respectively, P < .0001). On multivariate analysis, log-CCS and mid-LV hyperemic MBF increase, indicative of microvascular function, were independent predictors of the observed longitudinal MBF difference (P ≤ .004 by ANOVA). Conclusions. Epicardial structural disease and microvascular function are important determinants of an abnormal longitudinal MBF difference as determined with PET/CT. (J Nucl Cardiol 2010;17:1023-33.)
AB - Background. The aim of this study was to determine whether epicardial structural disease may affect the manifestation of a longitudinal decrease in myocardial blood flow (MBF) or MBF difference during hyperemia in cardiovascular risk individuals, and its dependency on the flow increase. Methods and Results. In 54 cardiovascular risk individuals (at risk) and in 26 healthy controls, MBF was measured with 13N-ammonia and PET/CT in mL/g/min at rest and during dipyridamole stimulation. Computed tomography coronary angiography (CTA) was performed using a 64-slice CT of a PET/CT system. Absolute MBFs during dipyridamole stimulation were mildly lower in the mid-distal than in the mid-LV myocardium in controls (2.20 ± .51 vs 2.29 ± .51, P < .0001), while it was more pronounced in at risk with normal and abnormal CTA (1.56 ± .42 vs 1.91 ± .46 and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respectively, P < .0001), resulting in a longitudinal MBF difference that was highest in at risk with normal CTA, intermediate in at risk abnormal CTA, and lowest in controls (.35 ± .16 and .22 ± .09 vs .09 ± .04 mL/g/min, respectively, P < .0001). On multivariate analysis, log-CCS and mid-LV hyperemic MBF increase, indicative of microvascular function, were independent predictors of the observed longitudinal MBF difference (P ≤ .004 by ANOVA). Conclusions. Epicardial structural disease and microvascular function are important determinants of an abnormal longitudinal MBF difference as determined with PET/CT. (J Nucl Cardiol 2010;17:1023-33.)
KW - Coronary artery disease
KW - Coronary circulation
KW - Endothelial function
KW - Myocardial blood flow
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=78651266821&partnerID=8YFLogxK
U2 - 10.1007/s12350-010-9272-9
DO - 10.1007/s12350-010-9272-9
M3 - Article
C2 - 20658271
AN - SCOPUS:78651266821
VL - 17
SP - 1023
EP - 1033
JO - Journal of Nuclear Cardiology
JF - Journal of Nuclear Cardiology
SN - 1071-3581
IS - 6
ER -